|
- ALZFORUM | NETWORKING FOR A CURE
A large proteogenomic study identified 49 pQTLs, in either CSF or plasma, linked to cerebral small vessel disease Immune and ECM proteins predominated
- The Discovery and Development of Liraglutide and Semaglutide . . . - ALZFORUM
Knudsen LB, Lau J The Discovery and Development of Liraglutide and Semaglutide Front Endocrinol (Lausanne) 2019;10:155 Epub 2019 Apr 12 PubMed
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the . . .
Zhang L, Zhang L, Li L, Hölscher C Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease J Parkinsons Dis 2019;9 (1):157-171
- Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction . . .
Rubin R Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? JAMA 2024 May 14;331 (18):1519-1521 PubMed
- Therapeutics - ALZFORUM
AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
- Exenatide - ALZFORUM
The short-acting form of exenatide is administered by twice-daily subcutaneous self-injection; a long-acting preparation is injected just once a week In mice, exenatide readily crossed the blood-brain barrier, while other GLP-1 mimetics liraglutide and semaglutide did not (Salameh et al , 2020)
- Empagliflozin - ALZFORUM
Empagliflozin belongs to the gliflozin class of glucose-lowering agents that includes dapagliflozin These drugs inhibit the sodium-glucose cotransporter-2 (SGLT2), which is responsible for 90 percent of glucose reabsorption into the kidney As a result, excess glucose is secreted via the urine, helping reduce blood glucose, alleviate glucose toxicity, improve insulin sensitivity, and promote
|
|
|